Positive News SentimentPositive News Hookipa Pharma Stock Price, News & Analysis (NASDAQ:HOOK) $0.57 +0.01 (+1.77%) (As of 12/1/2023 ET) Add Compare Share Share Today's Range$0.55▼$0.6050-Day Range$0.42▼$0.6352-Week Range$0.41▼$2.05Volume327,804 shsAverage Volume651,893 shsMarket Capitalization$48.27 millionP/E RatioN/ADividend YieldN/APrice Target$5.83 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Hookipa Pharma MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside914.5% Upside$5.83 Price TargetShort InterestHealthy0.31% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.02) to ($0.97) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.55 out of 5 starsMedical Sector180th out of 951 stocksPharmaceutical Preparations Industry71st out of 436 stocks 3.5 Analyst's Opinion Consensus RatingHookipa Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $5.83, Hookipa Pharma has a forecasted upside of 914.5% from its current price of $0.58.Amount of Analyst CoverageHookipa Pharma has only been the subject of 2 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.31% of the float of Hookipa Pharma has been sold short.Short Interest Ratio / Days to CoverHookipa Pharma has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Hookipa Pharma has recently decreased by 26.70%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldHookipa Pharma does not currently pay a dividend.Dividend GrowthHookipa Pharma does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for HOOK. Previous Next 3.3 News and Social Media Coverage News SentimentHookipa Pharma has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.76 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Hookipa Pharma this week, compared to 1 article on an average week.Search InterestOnly 2 people have searched for HOOK on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.MarketBeat Follows2 people have added Hookipa Pharma to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Hookipa Pharma insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.82% of the stock of Hookipa Pharma is held by insiders.Percentage Held by Institutions83.02% of the stock of Hookipa Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Hookipa Pharma are expected to grow in the coming year, from ($1.02) to ($0.97) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Hookipa Pharma is -0.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Hookipa Pharma is -0.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioHookipa Pharma has a P/B Ratio of 0.51. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Hookipa Pharma Stock (NASDAQ:HOOK)HOOKIPA Pharma Inc., a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in preclinical studies for the treatment of human papillomavirus-positive cancers. The company has a collaboration with Gilead Sciences, Inc. to develop arenavirus based therapeutics to treat hepatitis B virus and human immunodeficiency virus infections. HOOKIPA Pharma Inc. was founded in 2011 and is headquartered in New York, New York.Read More HOOK Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart HOOK Stock News HeadlinesNovember 20, 2023 | markets.businessinsider.comHOOKIPA Pharma: HB-500 IND Application Gets FDA Clearance To Treat HIVNovember 20, 2023 | finance.yahoo.comHOOKIPA Pharma Announces FDA Clearance of its Investigational New Drug Application for HB-500 for the Treatment of Human Immunodeficiency VirusDecember 2, 2023 | Wealthpress (Ad)Trading Experts Call It “The Perfect Tesla Trade”Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.November 12, 2023 | markets.businessinsider.comPromising Clinical Trials and Strong Financial Performance Bolster Buy Rating for Hookipa PharmaNovember 10, 2023 | markets.businessinsider.comHOOKIPA Pharma Reports Third Quarter 2023 Financial Results and Recent Business HighlightsNovember 9, 2023 | finanznachrichten.deHOOKIPA Pharma Inc.: HOOKIPA Pharma Reports Third Quarter 2023 Financial Results and Recent Business HighlightsNovember 9, 2023 | msn.comHOOKIPA Pharma GAAP EPS of -$0.17 beats by $0.03, revenue of $6.87M beats by $2.62MNovember 9, 2023 | finance.yahoo.comHOOKIPA Pharma Reports Third Quarter 2023 Financial Results and Recent Business HighlightsDecember 2, 2023 | Wealthpress (Ad)Trading Experts Call It “The Perfect Tesla Trade”Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.November 9, 2023 | finance.yahoo.comHOOKIPA Pharma Inc. Reports Increased Revenue and Higher R&D Expenses in Q3 2023November 3, 2023 | finance.yahoo.comHOOKIPA Pharma Presents Positive Biomarker and Translational Data on HB-200 Monotherapy at Society for Immunotherapy of Cancer 2023November 2, 2023 | finance.yahoo.comHOOKIPA Pharma to Report Third Quarter 2023 Financial Results and Recent Business Highlights on November 9, 2023October 22, 2023 | finance.yahoo.comHOOKIPA Pharma Presents Additional Preliminary Phase 2 Data on HB-200 in Combination with Pembrolizumab as First-Line Treatment in Patients with HPV16+ Head and Neck Cancers at European Society for Medical Oncology Congress 2023October 18, 2023 | finance.yahoo.comHOOKIPA Pharma announces publication of preclinical data of hepatitis B virus (HBV) therapeutic vaccine developed in collaboration with Gilead SciencesSeptember 27, 2023 | markets.businessinsider.comAnalyst Ratings for HOOKIPA PharmaSeptember 27, 2023 | markets.businessinsider.comRBC Capital Keeps Their Buy Rating on Hookipa Pharma (HOOK)September 13, 2023 | finanznachrichten.deHOOKIPA Pharma Inc.: HOOKIPA Announces Executive Leadership ChangeSeptember 13, 2023 | finance.yahoo.comHOOKIPA Announces Executive Leadership ChangeSeptember 12, 2023 | finanznachrichten.deHOOKIPA Pharma Inc.: HOOKIPA Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)September 12, 2023 | finance.yahoo.comHOOKIPA Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)August 15, 2023 | finance.yahoo.comSome Analysts Just Cut Their HOOKIPA Pharma Inc. (NASDAQ:HOOK) EstimatesAugust 12, 2023 | markets.businessinsider.comRBC Capital Reaffirms Their Buy Rating on Hookipa Pharma (HOOK)August 11, 2023 | msn.comHC Wainwright & Co. Maintains Hookipa Pharma (HOOK) Buy RecommendationAugust 10, 2023 | finanznachrichten.deHOOKIPA Pharma Inc.: HOOKIPA Pharma Reports Second Quarter 2023 Financial Results and Recent Business HighlightsAugust 10, 2023 | finance.yahoo.comHOOKIPA Pharma Inc. (HOOK) Reports Q2 Loss, Lags Revenue EstimatesAugust 10, 2023 | finance.yahoo.comHOOKIPA Pharma Reports Second Quarter 2023 Financial Results and Recent Business HighlightsAugust 3, 2023 | finance.yahoo.comHOOKIPA Pharma to Report Second Quarter 2023 Financial Results and Recent Business Highlights on August 10, 2023See More Headlines Receive HOOK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Hookipa Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/09/2023Today12/02/2023Fiscal Year End12/31/2023Next Earnings (Estimated)3/20/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:HOOK CUSIPN/A CIK1760542 Webwww.hookipapharma.com Phone431-890-6360Fax43-1890-636-0399Employees56Year FoundedN/APrice Target and Rating Average Stock Price Target$5.83 High Stock Price Target$7.00 Low Stock Price Target$4.00 Potential Upside/Downside+914.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.83) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-64,920,000.00 Net Margins-336.12% Pretax Margin-334.01% Return on Equity-70.24% Return on Assets-40.12% Debt Debt-to-Equity RatioN/A Current Ratio3.44 Quick Ratio3.44 Sales & Book Value Annual Sales$14.25 million Price / Sales3.39 Cash FlowN/A Price / Cash FlowN/A Book Value$1.13 per share Price / Book0.51Miscellaneous Outstanding Shares83,950,000Free Float79,064,000Market Cap$48.27 million OptionableNot Optionable Beta0.89 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesMr. Joern Aldag (Age 60)Pres, CEO & Director Mr. Daniel Pinschewer (Age 44)Founder & Chief Scientific Officer Dr. Reinhard Kandera (Age 50)CFO & Director Mr. Anders Lilja Ph.D. (Age 46)Sr. VP of Technical Devel. Mrs. Nina WaibelCommunications & Investor Relations Mang.Key CompetitorsCelularityNASDAQ:CELUHCW BiologicsNASDAQ:HCWBLantern PharmaNASDAQ:LTRNFibroGenNASDAQ:FGENMEI PharmaNASDAQ:MEIPView All CompetitorsInsiders & InstitutionsArmistice Capital LLCSold 144,000 shares on 11/15/2023Ownership: 4.422%Redmile Group LLCSold 2,224,700 shares on 11/15/2023Ownership: 1.267%FMR LLCSold 1,469,061 shares on 11/13/2023Ownership: 4.000%Group One Trading L.P.Sold 100 shares on 11/9/2023Ownership: 0.000%Simplex Trading LLCSold 600 shares on 11/1/2023Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions HOOK Stock Analysis - Frequently Asked Questions Should I buy or sell Hookipa Pharma stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Hookipa Pharma in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" HOOK shares. View HOOK analyst ratings or view top-rated stocks. What is Hookipa Pharma's stock price target for 2024? 3 Wall Street research analysts have issued twelve-month price targets for Hookipa Pharma's shares. Their HOOK share price targets range from $4.00 to $7.00. On average, they expect the company's share price to reach $5.83 in the next twelve months. This suggests a possible upside of 914.5% from the stock's current price. View analysts price targets for HOOK or view top-rated stocks among Wall Street analysts. How have HOOK shares performed in 2023? Hookipa Pharma's stock was trading at $0.81 on January 1st, 2023. Since then, HOOK shares have decreased by 29.0% and is now trading at $0.5750. View the best growth stocks for 2023 here. When is Hookipa Pharma's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 20th 2024. View our HOOK earnings forecast. How were Hookipa Pharma's earnings last quarter? Hookipa Pharma Inc (NASDAQ:HOOK) posted its quarterly earnings results on Thursday, November, 9th. The company reported ($0.17) earnings per share for the quarter, beating analysts' consensus estimates of ($0.23) by $0.06. The firm earned $6.87 million during the quarter, compared to the consensus estimate of $3.39 million. Hookipa Pharma had a negative trailing twelve-month return on equity of 70.24% and a negative net margin of 336.12%. What other stocks do shareholders of Hookipa Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Hookipa Pharma investors own include Homology Medicines (FIXX), Kaleido Biosciences (KLDO), Editas Medicine (EDIT), Gossamer Bio (GOSS), Atreca (BCEL), LogicBio Therapeutics (LOGC), Alector (ALEC), Precision BioSciences (DTIL), Akero Therapeutics (AKRO) and Dynavax Technologies (DVAX). When did Hookipa Pharma IPO? (HOOK) raised $100 million in an initial public offering (IPO) on Thursday, April 18th 2019. The company issued 6,700,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, SVB Leerink and RBC Capital Markets acted as the underwriters for the IPO and Kempen was co-manager. Who are Hookipa Pharma's major shareholders? Hookipa Pharma's stock is owned by a variety of retail and institutional investors. Top institutional investors include Armistice Capital LLC (4.42%), FMR LLC (4.00%), Redmile Group LLC (1.27%), Group One Trading L.P. (0.00%), Simplex Trading LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Igor Matushansky, Jorn Aldag, Reinhard Kandera and Sofinnova Capital Vi Fcpr. View institutional ownership trends. How do I buy shares of Hookipa Pharma? Shares of HOOK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:HOOK) was last updated on 12/2/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hookipa Pharma Inc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.